Key Laboratory for Reproductive Medicine and Embryo of Gansu, First Affiliated Hospital, Lanzhou University, No.1, Donggangxi Rd, Chengguan District, Lanzhou City, Gansu, 730000, People's Republic of China.
Reprod Sci. 2022 Oct;29(10):2760-2767. doi: 10.1007/s43032-021-00717-w. Epub 2022 Jan 1.
Ovarian cancer (OC) is a highly malignant disease that seriously threatens women's health and poses challenges for clinicians. MicroRNAs (miRNAs) have recently been intensively studied in the field of oncology due to their regulatory roles in gene expressions through RNA degradation and/or translation inhibition. This review summarizes the current studies on miRNAs in OC and introduces the latest updates of miRNAs in the early screening, treatment, and prognostic prediction of OC, thereby demonstrating the clinical significance of miRNAs in OC. Further exploration on potential targets of miRNAs in OC may provide new insights on optimizing the diagnosis and treatment of OC. MiRNAs are important driving factors for the progression of OC and the dysregulation of miRNAs can serve as biomarkers in the diagnosis, treatment and prognosis of OC. Therefore, miRNAs are potential biological targets for early screening, targeted therapy, drug resistance monitoring, and prognosis improvement in malignancies such as OC.
卵巢癌（OC）是一种高度恶性的疾病，严重威胁着妇女的健康，给临床医生带来了挑战。微小 RNA（miRNA）由于其通过 RNA 降解和/或翻译抑制在基因表达中的调节作用，最近在肿瘤学领域得到了深入研究。本综述总结了 miRNA 在 OC 中的研究现状，并介绍了 miRNA 在 OC 的早期筛查、治疗和预后预测中的最新进展，从而展示了 miRNA 在 OC 中的临床意义。进一步探索 miRNA 在 OC 中的潜在靶点可能为优化 OC 的诊断和治疗提供新的思路。miRNA 是 OC 进展的重要驱动因素，miRNA 的失调可以作为 OC 的诊断、治疗和预后的生物标志物。因此，miRNA 是 OC 等恶性肿瘤早期筛查、靶向治疗、耐药监测和预后改善的潜在生物学靶点。
